Riliprubart

Monoclonal antibody

Also known as SAR445088

Phase 3underway

Evidence outlook · registrational

Chronic Inflammatory Demyelinating Polyneuropathy: registrational readout pending

Its supporting mid-stage studies have completed. Registrational readout expected around 2027-07-09.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (3)
Chronic Inflammatory Demyelinating Polyneuropathy
NCT06290141 · Sanofi
2024-08-21 – 2029-01-12 · Chronic Inflammatory Demyelinating Polyneuropathy
What this study did
NCT06290128 · Sanofi
2024-07-12 – 2027-10-31 · Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Polyneuropathy, Inflammatory Demyelinating, Chronic
What this study did
Other / comorbidity
NCT06859099 · Sanofi
2025-04-01 – 2029-10-03 · Polyneuropathy, Inflammatory Demyelinating, Chronic
What this study did
Phase 2 (3)
Chronic Inflammatory Demyelinating Polyneuropathy
NCT04658472 · Bioverativ, a Sanofi company
2021-04-28 – 2025-10-01 · Chronic Inflammatory Demyelinating Polyradiculoneuropathy
What this study did
Other / comorbidity
NCT05156710 · Sanofi
2022-06-09 – 2026-10-20 · Transplant Rejection
What this study did
NCT04669600 · Bioverativ, a Sanofi company
2021-02-04 – 2023-02-07 · Immune Thrombocytopenia (ITP)
What this study did
Phase 1 (1)
Other / comorbidity
NCT04802057 · Bioverativ, a Sanofi company
2021-03-22 – 2025-03-04 · Autoimmune Haemolytic Anaemia
What this study did

Competitive landscape

This drug's own stage for Chronic Inflammatory Demyelinating Polyneuropathy: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Riliprubart: this drugPhase 3Monoclonal antibodyComplement C1snot yet gradedNo reviewed efficacy summary in this indication
Efgartigimod Alfa (Vyvgart)
Approved(overall)
Antibody fragmentFcRnnot yet gradedNo reviewed efficacy summary in this indication
Efgartigimod Alfa And Hyaluronidase (Vyvgart Hytrulo)ApprovedAntibody fragmentFcRnnot yet gradedNo reviewed efficacy summary in this indication
ImeroprubartPhase 2Monoclonal antibodyFcRnnot yet gradedNo reviewed efficacy summary in this indication
TAK-411
—(overall)
Biologic (subtype unspecified)—not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Riliprubart to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
July 2027 (1)
Phase 3Chronic Inflammatory Demyelinating PolyneuropathyRecruiting
Est. primary completion 2027-07-09 · NCT06290141 · CT.gov ↗
What to watch
2029 (1)
October 2029 (1)
Phase 3Polyneuropathy, Inflammatory Demyelinating, ChronicEnrolling by invitation
Est. primary completion 2029-10-03 · NCT06859099 · CT.gov ↗
What to watch

See the full readout calendar ↗